Search Keyword:


Search option:


IID00244
UniprotQ13177
ProteinSerine/threonine-protein kinase PAK 2
GenePAK2
OrganismHomo sapiens
Sequence LLPS PhaSepDB
PhaSePro
LLPSDB
DrLLPS
Network xml rdf
Structure
Experiment
  :order   disorder   conflict   PDB cluster   ProS   Pfam Domain   SEG
524
 order/disorder by at least rule
     disorder by at least rule
     order by at least rule
 order/disorder by majority rule
Seq 121-136 Hetero dimer : Q7DB50
 Evidence X-RAY 3pcs E Reference
       Region 3pcs E 121-121 disorder
       Region 3pcs E 122-135 order
       Region 3pcs E 136-136 disorder
 Evidence X-RAY 3pcs F Reference
       Region 3pcs F 121-121 disorder
       Region 3pcs F 122-133 order
       Region 3pcs F 134-136 disorder
 Evidence X-RAY 3pcs G Reference
       Region 3pcs G 121-122 disorder
       Region 3pcs G 123-132 order
       Region 3pcs G 133-136 disorder
 Evidence X-RAY 3pcs H Reference
       Region 3pcs H 121-121 disorder
       Region 3pcs H 122-134 order
       Region 3pcs H 135-136 disorder
Seqphosphorylation
    402-402 Phosphothreonine; by autocatalysis
    197-197 Phosphoserine
    169-169 Phosphothreonine
    154-154 Phosphothreonine
    152-152 Phosphoserine
    143-143 Phosphothreonine
    141-141 Phosphoserine
    139-139 Phosphotyrosine
    134-134 Phosphothreonine
    64-64 Phosphoserine
    60-60 Phosphothreonine
    58-58 Phosphoserine
    55-55 Phosphoserine
    20-20 Phosphoserine
    2-2 Phosphoserine
    2-2 Phosphoserine
    20-20 Phosphoserine
    55-55 Phosphoserine
    58-58 Phosphoserine
    60-60 Phosphothreonine
    64-64 Phosphoserine
    134-134 Phosphothreonine
    139-139 Phosphotyrosine
    141-141 Phosphoserine
    143-143 Phosphothreonine
    152-152 Phosphoserine
    154-154 Phosphothreonine
    169-169 Phosphothreonine
    197-197 Phosphoserine
    402-402 Phosphothreonine; by autocatalysis
Seqacetylation
    128-128 N6-acetyllysine
    62-62 N6-acetyllysine
    2-2 N-acetylserine
    2-2 N-acetylserine
    62-62 N6-acetyllysine
    128-128 N6-acetyllysine
 
Prediction
NeProc
Disorder 1-79,110-132,137-224,518-524
Order 80-109,133-136,225-517
ProS 7-18,72-79,110-132,137-153,177-184,214-224,518-524
AlphaFold
Disorder 1-72,80-84,132-225,523-524
Order 73-79,85-131,226-522
Pfam Hmmer
PF00786 73-131 4.9e-31
PF00069 249-500 7.9e-99
SEG 58-70 ,162-182
Function
Function in SwissProt
Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell motility, cell cycle progression, apoptosis or proliferation (PubMed:7744004, PubMed:19273597, PubMed:19923322, PubMed:9171063, PubMed:12853446, PubMed:16617111, PubMed:33693784). Acts as a downstream effector of the small GTPases CDC42 and RAC1 (PubMed:7744004). Activation by the binding of active CDC42 and RAC1 results in a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues (PubMed:7744004). Full-length PAK2 stimulates cell survival and cell growth (PubMed:7744004). Phosphorylates MAPK4 and MAPK6 and activates the downstream target MAPKAPK5, a regulator of F-actin polymerization and cell migration (PubMed:21317288). Phosphorylates JUN and plays an important role in EGF-induced cell proliferation (PubMed:21177766). Phosphorylates many other substrates including histone H4 to promote assembly of H3.3 and H4 into nucleosomes, BAD, ribosomal protein S6, or MBP (PubMed:21724829). Phosphorylates CASP7, thereby preventing its activity (PubMed:21555521, PubMed:27889207). Additionally, associates with ARHGEF7 and GIT1 to perform kinase-independent functions such as spindle orientation control during mitosis (PubMed:19273597, PubMed:19923322). On the other hand, apoptotic stimuli such as DNA damage lead to caspase-mediated cleavage of PAK2, generating PAK-2p34, an active p34 fragment that translocates to the nucleus and promotes cellular apoptosis involving the JNK signaling pathway (PubMed:9171063, PubMed:12853446, PubMed:16617111). Caspase-activated PAK2 phosphorylates MKNK1 and reduces cellular translation (PubMed:15234964).